Aalto Bio Reagents Ltd., one of the largest providers of raw materials and controls to the in vitro diagnostics industry and research laboratories, recently announced the first full range of Hepatitis B Virus (HBV) human plasma intended for production of positive controls and QC in the industry.
“Our HBV-positive human plasma has been collected from donors by a method called plasmapheresis,” Sarah McElroy, head of sales and marketing at Aalto Bio Reagents, told Patient Daily. “There is no processing done following collection and it is sold to our customers as a raw material.”
Once the material is collected and sold, those companies then “use it to make controls for their diagnostic test kits or else to build a QC panel,” McElroy said.
Person-to-person transmission of HBV through blood and other bodily fluids and infection can be classed as acute or chronic, depending on the longevity of the virus, McElroy told Patient Daily.
Citing World Health Organization research, an Aalto Bio Reagents representative explained that there are over four million acute clinical cases of HBV, and about one million people a year die from chronic active hepatitis, cirrhosis or primary liver cancer. Because of this, the availability of materials is important to further improve research that can produce diagnostic products needed in the medical market at a faster rate.
Headquartered in Dublin, Ireland, Aalto Bio Reagents provides a broad range of purified human proteins; monoclonal and polyclonal antibodies; fungal, parasitic, bacterial and viral antigens; disease state plasma and molecular controls for in vitro diagnostic application.
